MedAI Verdict

Clinical Decision Support · 57 tools

Editorial illustration: a magnifying glass over an anatomical heart, with a branching differential-diagnosis tree leading to ischemic, valvular, and inflammatory etiologies.

AITRICS-VC (VitalCare)

AITRICS-VC (VitalCare) logo
28/ 100

Evidence & Documentation Score

This legacy score reflects documented evidence, integrations, transparency, and market signals. It does not measure overall product performance. A new product-focused rating system is in development. How it is computed

reviewed November 2, 2026

Vendor
AITRICS, KR
Pricing
No public price. No pricing page was found on the site.
EHR
Not stated
Compliance
FDA 510(k)

Bottom line. AITRICS-VC, sold as VitalCare by the Seoul company AITRICS, reads hospital EMR data and lists ward patients at risk of deterioration. FDA cleared it in July 2024 through a 510(k), yet the company's homepage does not mention the FDA. It lists approvals in Malaysia (May 2026) and Indonesia (April 2026) and memoranda of understanding in Hong Kong, so a hospital… Read the full bottom line

Performance profile

  • Regulatory and compliance12 / 22
  • Clinical integration0 / 11.6
  • Evidence strength0 / 30
  • Vendor and market8.4 / 12
  • Sentiment and transparency1.3 / 2.5

Performance profile

  • Regulatory and compliance12 / 22
  • Clinical integration0 / 11.6
  • Evidence strength0 / 30
  • Vendor and market8.4 / 12
  • Sentiment and transparency1.3 / 2.5
On this page

All 9 dimensions

Regulatory and compliance

  • FDA clearance12 / 12

    FDA cleared (1 510(k) clearance on record)

  • HIPAA / SOC2 / BAA0 / 10

    No public HIPAA/SOC2/BAA attestation

Clinical integration

  • EHR integrations (count)0 / 5.6

    No EHR integrations listed

  • Top-3 EHR coverage (Epic / Oracle / Athena)0 / 4.8

    None of the top-3 EHRs covered

  • Bidirectional write-back0 / 1.2

    No bidirectional write-back documented

Evidence strength

  • Peer-reviewed papers0 / 21

    No peer-reviewed paper evaluating the product

  • RCT / meta-analysis / systematic review0 / 9

    No RCT, meta-analysis, or systematic review evaluating the product

Vendor and market

  • Funding & adoption signal8.4 / 12

    Mid-tier funding and adoption

Sentiment and transparency

  • Pricing transparency1.3 / 2.5

    Pricing on request, no public amounts

Computed November 6, 2026 by our public rubric. How it’s computed

What it costs

From
No public price. No pricing page was found on the site.
Price points
1
Verified
November 2, 2026
Source
Vendor pricing page

All tiers are custom-quoted. The vendor does not publish per-provider list pricing.

TierMonthlyAnnualNotes
EnterpriseNot statedNot statedNo public price. No pricing page was found on the site.

Source: vendor pricing page. Last checked November 2, 2026.

Compliance

Attested
FDA 510(k)
EHR integrations
Not stated
FDA
1 decision on record

Carries FDA 510(k) per vendor documentation. Independent attestation review is the buyer's responsibility before clinical deployment.

Vendor stability

Company
AITRICS
Headquarters
KR
Founded
Not stated

Vendor sitewww.aitrics.com (opens in new tab)

Evidence record

RecordWhat we found
FDA decisions
Verification
  • Score computed November 6, 2026, method 1.2.1
  • Review written November 2, 2026
Cite this record

MedAI Verdict, AITRICS-VC (VitalCare) record, https://medaiverdict.com/tools/aitrics-vitalcare, version November 2, 2026

Change historyView every change to this record

Bottom line

AITRICS-VC, sold as VitalCare by the Seoul company AITRICS, reads hospital EMR data and lists ward patients at risk of deterioration. FDA cleared it in July 2024 through a 510(k), yet the company's homepage does not mention the FDA. It lists approvals in Malaysia (May 2026) and Indonesia (April 2026) and memoranda of understanding in Hong Kong, so a hospital in those markets is the clearest match. A US hospital that wants a named domestic site has none to look at.

Stand-alone software that analyzes hospital EMR data and lists ward patients at risk of deterioration. Not for ICU or operating room use.

No public price. No pricing page was found on the site.

Where does the US clearance stand?

K240756 is dated July 23, 2024, under the applicant name Aitrics Co., Ltd., for "AITRICS-VC" (21 CFR 870.2300, product code PLB, "Multivariate Vital Signs Index"). The predicate is Capsule Surveillance System (K213335). Korean press reports an MFDS approval in October 2022, which has not been verified on an official page. The homepage lists the Malaysian MDA and Indonesian Ministry of Health approvals instead of the US one.

What does the cleared software do?

The FDA indication describes stand-alone software that analyzes patient data from the EHR and displays in-hospital patients whose vital signs, laboratory values or conventional early warning scores (MEWS, NEWS, qSOFA) exceed thresholds. It does not replace bedside monitors and is not for ICU or operating room use. Korean press describes the underlying risk model as predicting sepsis, death and cardiac arrest. The Korean homepage, translated, reads "AI analyzes real-time EMR data accumulated in hospitals to predict patient deterioration". No EHR vendor is named.

Planned work under an "AX" project with Gangbuk Samsung Hospital covers outpatient record summaries, CT and MRI report summaries and nursing handover support. A clinician copilot called V.Doc Pro appears in Korean press.

Which papers name VitalCare?

Six 2025 and 2026 papers on deterioration and sepsis models name VitalCare in the title or abstract, and their author affiliations have not been checked. Three examples:

  • PMID 40494595 (Acute and Critical Care, 2025), prospective external validation of a deep-learning early warning system for major adverse events in general wards.
  • PMID 40541404 (BMJ Health & Care Informatics, 2025), an AI algorithm for sepsis risk stratification.
  • PMID 40845828 (JMIR Medical Informatics, 2025), deep-learning early warning for code blue events and length of stay.

PMID 42513667 (J Clin Med, 2026), on a workload-constrained cutoff for deterioration AI, is also listed on the vendor's site, and several of the six are vendor-linked.

Company and funding

AITRICS Inc. is in Gangnam-gu, Seoul, with Kim Kwang-jun as CEO. Korean press gives 2016 as the founding year, a Series B of KRW 27.1 billion in March 2024 and a Series C of KRW 35 billion announced on December 1, 2025. The homepage names memoranda of understanding with the HKU Faculty of Medicine CHART and Glen Eagles Hospital in Hong Kong, and a mention in TIME's "World's Best Health Tech Companies 2026". It gives no customer count and no price.

The verdict

The verifiable footprint is the Malaysian and Indonesian approvals the homepage lists, the Hong Kong memoranda and the July 2024 US clearance, while the Korean MFDS approval is unverified. Author affiliations on the six papers are unchecked, which leaves independent validation an open question.

Editorial review last generated November 2, 2026. Synthesized from clinician sentiment, peer-reviewed coverage, and our editorial silo picks. Refined by hand where vendor facts change.

Link to this review

AITRICS-VC (VitalCare), reviewed on MedAI Verdict

Vendors may place this badge on their own site. It links to this review with a tracking parameter and has no effect on the score.

<a href="https://medaiverdict.com/tools/aitrics-vitalcare?utm_source=vendor_badge&utm_medium=badge&utm_campaign=aitrics-vitalcare"><img src="https://medaiverdict.com/badges/reviewed-on-medaiverdict.png" srcset="https://medaiverdict.com/badges/reviewed-on-medaiverdict@2x.png 2x" alt="AITRICS-VC (VitalCare), reviewed on MedAI Verdict" width="200" height="56"></a>

What we have not verified

  1. We have not run AITRICS-VC (VitalCare) in our own clinical practice. Pricing, certifications, and EHR-integration claims come from vendor documentation and have not been independently audited.
  2. Enterprise pricing tiers and SLA terms are typically under NDA and not publicly verifiable. Numbers shown reflect publicly disclosed self-service or list pricing only.
  3. Real-world latency, note quality, and accuracy in your specific specialty and patient population can vary materially from vendor demonstrations. We recommend a 30-day trial with two providers before commitment.

Last verified . Read our methodology · Decision support